MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 145593 | Name: EAPB-0202

Description:

WARNING: This product is for research use only, not for human or veterinary use.

EAPB-0202 is a demethylated metabolite of EAPB0203. EAPB-0202 shows significant in vitro activities against A375 compared to fotemustine and imiquimod used as references.

Chemical Structure

EAPB-0202
EAPB-0202
CAS#681284-82-2

Theoretical Analysis

MedKoo Cat#: 145593

Name: EAPB-0202

CAS#: 681284-82-2

Chemical Formula: C18H16N4

Exact Mass: 288.1400

Molecular Weight: 288.35

Elemental Analysis: C, 74.98; H, 5.59; N, 19.43

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
EAPB-0202; EAPB0202; EAPB 0202;
IUPAC/Chemical Name
1-phenethylimidazo[1,2-a]quinoxalin-4-amine
InChi Key
KJNPWZYCMKZTBJ-UHFFFAOYSA-N
InChi Code
1S/C18H16N4/c19-17-18-20-12-14(11-10-13-6-2-1-3-7-13)22(18)16-9-5-4-8-15(16)21-17/h1-9,12H,10-11H2,(H2,19,21)
SMILES Code
NC1=NC2=C(C=CC=C2)N3C(CCC4=CC=CC=C4)=CN=C13
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 288.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Moarbess G, Deleuze-Masquefa C, Bonnard V, Gayraud-Paniagua S, Vidal JR, Bressolle F, Pinguet F, Bonnet PA. In vitro and in vivo anti-tumoral activities of imidazo[1,2-a]quinoxaline, imidazo[1,5-a]quinoxaline, and pyrazolo[1,5-a]quinoxaline derivatives. Bioorg Med Chem. 2008 Jul 1;16(13):6601-10. doi: 10.1016/j.bmc.2008.05.022. Epub 2008 May 10. PMID: 18513976. 2: Lafaille F, Banaigs B, Inguimbert N, Enjalbal C, Doulain PE, Bonnet PA, Masquefa C, Bressolle FM. Characterization of a new anticancer agent, EAPB0203, and its main metabolites: nuclear magnetic resonance and liquid chromatography- mass spectrometry studies. Anal Chem. 2012 Nov 20;84(22):9865-72. doi: 10.1021/ac3021483. Epub 2012 Oct 31. PMID: 23072539. 3: Khier S, Deleuze-Masquéfa C, Moarbess G, Gattacceca F, Margout D, Solassol I, Cooper JF, Pinguet F, Bonnet PA, Bressolle FM. Pharmacology of EAPB0203, a novel imidazo[1,2-a]quinoxaline derivative with anti-tumoral activity on melanoma. Eur J Pharm Sci. 2010 Jan 31;39(1-3):23-9. doi: 10.1016/j.ejps.2009.10.006. Epub 2009 Oct 23. PMID: 19854270. 4: Kaneko D, Ninomiya M, Yoshikawa R, Ono Y, Sonawane AD, Tanaka K, Nishina A, Koketsu M. Synthesis of [1,2,4]triazolo[4,3-a]quinoxaline-1,3,4-oxadiazole derivatives as potent antiproliferative agents via a hybrid pharmacophore approach. Bioorg Chem. 2020 Nov;104:104293. doi: 10.1016/j.bioorg.2020.104293. Epub 2020 Sep 19. PMID: 33010622. 5: Khier S, Gattacceca F, El Messaoudi S, Lafaille F, Deleuze-Masquéfa C, Bompart J, Cooper JF, Solassol I, Pinguet F, Bonnet PA, Bressolle FM. Metabolism and pharmacokinetics of EAPB0203 and EAPB0503, two imidazoquinoxaline compounds previously shown to have antitumoral activity on melanoma and T-lymphomas. Drug Metab Dispos. 2010 Oct;38(10):1836-47. doi: 10.1124/dmd.110.034579. Epub 2010 Jul 21. PMID: 20660102.